Rinvoq and Claritin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rinvoq (upadacitinib) and Claritin (loratadine). Common drug interactions include increased bronchial secretion among females and pain among males.

The phase IV clinical study analyzes what interactions people have when they take Rinvoq and Claritin. It is created by eHealthMe based on reports of 77 people who take the same drugs from the FDA, and is updated regularly.

What is Rinvoq?

Rinvoq has active ingredients of upadacitinib. eHealthMe is studying from 47,375 Rinvoq users. Check the latest studies of Rinvoq.

What is Claritin?

Claritin has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 77,315 Claritin users. Check the latest studies of Claritin.



On Jul, 12, 2026

77 people who take Rinvoq and Claritin together, and have interactions are studied.

Rinvoq and Claritin drug interactions.

What are the common drug interactions of Rinvoq and Claritin, by gender? *:

female:

  1. Increased bronchial secretion
  2. Influenza
  3. Ingrowing nail
  4. Joint swelling
  5. Lymphocytosis (an increase in the number or proportion of lymphocytes in the blood)
  6. Metamyelocyte count decreased (less than normal precursor in the granulocytic series)
  7. Migraine (headache)
  8. Monoclonal gammopathy
  9. Neutropenia (an abnormally low number of neutrophils)
  10. Oesophageal pain

male:

  1. Pain
  2. Pain in extremity
  3. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  4. Erythema (redness of the skin)
  5. Folliculitis (infection of hair root)
  6. Intervertebral disc protrusion (spinal disc protrusion)
  7. Limb discomfort (discomfort in leg)
  8. Papule
  9. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  10. Psoriasis (immune-mediated disease that affects the skin)

What are the common drug interactions of Rinvoq and Claritin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  2. Infection
  3. Tonsillar cyst (cyst on tonsil)
  4. Vitreous floaters (spots before the eyes)

20-29:

  1. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  2. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)
  3. Pain

30-39:

n/a

40-49:

  1. Blood calcium increased
  2. Cough
  3. Hypergammaglobulinaemia benign monoclonal (elevated levels of gamma globulin)
  4. Influenza
  5. Pruritus (severe itching of the skin)
  6. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

50-59:

  1. Asthma
  2. Carotid artery occlusion (artery blockage)
  3. Carotid artery thrombosis (blood clot in carotid artery)
  4. Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
  5. Device dislocation
  6. Dizziness
  7. Ear infection
  8. Gait disturbance
  9. Hypoacusis (loss of hearing)
  10. Hypoaesthesia (reduced sense of touch or sensation)

60+:

  1. Pain
  2. Pain in extremity
  3. Dizziness
  4. Escherichia urinary tract infection (urinary tract infection by escherichia coli)
  5. Herpes zoster
  6. Osteoporosis (bones weak and more likely to break)
  7. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  8. Pyelonephritis (inflammation of kidney caused by bacteria)
  9. Rash vesicular (rash with a small bubble)
  10. White blood cell count decreased

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 46 people, 59.74%
  2. Hypersensitivity: 22 people, 28.57%
  3. High Blood Cholesterol: 14 people, 18.18%
  4. Pain: 13 people, 16.88%
  5. High Blood Pressure: 13 people, 16.88%
  6. Diabetes: 9 people, 11.69%
  7. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 8 people, 10.39%
  8. Immunodeficiency Common Variable: 7 people, 9.09%
  9. Thyroid Diseases: 6 people, 7.79%
  10. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 6.49%

* Approximation only. Some reports may have incomplete information.

Do you take Rinvoq and Claritin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Rinvoq and Claritin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rinvoq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Claritin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rinvoq and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Claritin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on upadacitinib and loratadine (the active ingredients of Rinvoq and Claritin, respectively), and Rinvoq and Claritin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: